semaglutide discontinuation effects What are the long-term side of after 3+ years semaglutide discontinuation effects SELECT Trial

It stimulates lipolysis (breakdown of stored fats) and inhibits lipogenesis (formation of new fat), primarily via activation of -adrenergic and AMP-activated protein kinase (AMPK) pathways

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, and in adolescents aged 12 years and older with obesity

---- Both of these GLP1's have had trials demonstrating positive CV benefits (SUSTAIN6 and REWIND trials)

c Data are for the in-trial period (the time from randomization to last contact with trial site, irrespective of treatment discontinuation or rescue intervention)